GHRP-2

GHRP-2, also known as Growth Hormone Releasing Peptide 2, Pralmorelin, or KP-102, is a growth hormone peptide extensively studied in laboratory settings for its effects on growth hormone secretion. This synthetic peptide operates through a well-defined mechanism involving the growth hormone secretagogue receptor (GHS-R) on pituitary cells. In research models, GHRP-2 demonstrates its primary function by binding to GHS-R receptors, effectively stimulating the release of growth hormone. The peptide mimics the action of ghrelin, a naturally occurring hormone that regulates appetite and energy balance, thereby facilitating increased growth hormone levels. Additionally, studies indicate that GHRP-2 influences hypothalamic function to further enhance growth hormone secretion. Laboratory investigations have documented several primary research effects of GHRP-2 administration. These include increased growth hormone secretion as the primary mechanism, moderate appetite stimulation reflecting its ghrelin-mimetic properties, improved muscle-regulatory pathways development, enhanced recovery from exercise procedures, and potential lipolysis in experimental models. The current evidence grade for GHRP-2 is classified as C, indicating that whilst some promising research exists, comprehensive clinical trials remain limited. Available studies suggest the peptide effectively increases growth hormone levels and may improve body composition parameters in research settings. However, researchers note that more extensive investigation is required to fully confirm efficacy profiles and establish comprehensive safety parameters. This research-grade peptide continues to be of significant interest in growth hormone research, particularly for studies examining growth hormone regulation, body composition changes, and metabolic effects in controlled laboratory environments.